⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MDGL News
Madrigal Pharmaceuticals, Inc. Common Stock
Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH
prnewswire.com
MDGL
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
globenewswire.com
MDGL
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MDGL
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
globenewswire.com
MDGL
ReAlta Life Sciences Announces Appointment of Kia Motesharei, Ph.D. to Board of Directors
businesswire.com
MDGL
AKTX
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MDGL
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MDGL
Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
MDGL
Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor
globenewswire.com
MDGL
$18.67 Bn MASH Treatment Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029 & 2034
globenewswire.com
MDGL
NVO
LLY
AZN